Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
Legend Biotech will present late-breaking Phase 1 data for LB2501, an in vivo CAR-T therapy, at the EHA 2026 Congress in Stockholm. The data shows a 100% objective response rate and 83.3% complete response rate in the dose level 2 cohort of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Key figures
- Drug Name
- LB2501
- Phase Of Trial
- Phase 1
- Cr dl2
- 83.3%
- Orr dl2
- 100%
- Crs grade
- <Grade 2
- Sae observed
- No
- Dlts observed
- No
- Icans reported
- No
- Patients treated
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.